Back to news

Medicus Pharma Announces Closing of $4.25 Million CEO-Led Equity Financings and $10.5 Million Debt Exchange

Globe Newswire•16/11/2026•07:30 ET
0

Key Highlights

  • ➤$4.25 million equity financings closed, priced at-the-market at $1.72 per share
  • ➤CEO and insiders invested $1.25 million, including $750,000 from CEO Raza Bokhari
  • ➤Streeterville exchanged $10.5 million debt for 105,000 non-convertible preferred shares
  • ➤Medicus expects shareholders’ equity above Nasdaq’s $2.5 million continued-listing threshold
  • ➤Raza Bokhari’s ownership rose to 18.3% non-diluted after the transactions

Expert Statements

Raza Bokhari, Executive Chairman and Chief Executive Officer of Medicus Pharma Ltd.

“The investment reflects management’s and insiders’ support for the Company’s strategic direction, with CD228V, its investigational antibody-drug conjugate utilizing an established Vedotin platform, at the center of its precision oncology focus.”

CEO and other insiders lead private investment of $1.25 million, including $750,000 from the CEO, underscoring confidence in the Company’s precision oncology-led strategy, anchored by its CD228V development program.

PHILADELPHIA, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision-guided, biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced the closing of an aggregate of $4.25 million fixed-price equity financings priced at-the-market, including a private placement led by its Chief Executive Officer and other insiders. The private placement totaled $1.25 million, or approximately 30% of the total financings, and was made to a limited number of accredited investors consisting primarily of directors and officers of the Company, including $750,000 from Medicus’ Executive Chairman and Chief Executive Officer. Approximately $3.0 million of the financing was conducted via a registered direct offering pursuant to the Company’s shelf registration statement on Form S-3 and a prospectus supplement. The investment reflects management’s and insiders’ support for the Company’s strategic direction, with CD228V, its investigational antibody-drug conjugate utilizing an established Vedotin platform, at the center of its precision oncology focus.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in